|
Leveraging oncogenic mutant-ATRX driven collateral vulnerabilities to identify novel therapeutic approaches |
St. Jude Children’s Research Hospital |
Northwestern Mutual Foundation |
|
Characterizing determinants of response and therapeutic barriers to novel antibody-drug conjugates (ADCs) targeting the Anaplastic Lymphoma Kinase (ALK) oncoprotein in neuroblastoma |
Children’s Hospital of Philadelphia |
Northwestern Mutual Foundation |
|
Enhancing CAR T Cell Therapy for Diffuse Intrinsic Pontine Glioma by Promoting CAR T Cell Persistence with Novel Manufacturing Approach and Immune Checkpoint Receptor Modifications |
Seattle Children’s Hospital |
Northwestern Mutual Foundation |
|
Targeting KAT2A-Dependent Oncogenic Transcriptional Programs in Pediatric AML Using a Novel Molecular Glue Degrader |
Dana-Farber Cancer Institute |
Northwestern Mutual Foundation |
|
Modeling Clonal Hematopoiesis and Genetic Correction in RUNX1-FPD Using Human iPSC-derived HSCs |
Icahn School of Medicine at Mount Sinai |
The RUNX1 Research Program |
|
Epigenetic Targeting of Translation in Sarcomas |
Seattle Children’s Hospital |
Northwestern Mutual Foundation |
|
Investigating interactions between the oncogenic phosphatase PPM1D and oncohistone H3K27M in diffuse midline gliomagenesis |
Duke University |
Northwestern Mutual Foundation |
|
Targeting Fatty Acid Oxidation as a Metabolic Vulnerability in Pediatric Cancers |
Dana-Farber Cancer Institute |
Northwestern Mutual Foundation |
|
Identifying mechanisms of revumenib resistance in KMT2A-r pediatric acute myeloid leukemia (AML) |
The Johns Hopkins University School of Medicine |
Northwestern Mutual Foundation |
|
The immunosuppressive role of thrombospondin-2 in pulmonary metastatic osteosarcoma |
Children’s Hospital Los Angeles |
Northwestern Mutual Foundation |
